Compare Adaptive Biotechnologies Corp (ADPT) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Western Alliance Bancorporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Western Alliance Bancorporation trades at $78.82 (market cap $9.01B). The key difference: Western Alliance Bancorporation is far larger — about 2.7× Adaptive Biotechnologies Corp's market cap, and Western Alliance Bancorporation pays a 2.04% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WAL | |
|---|---|---|
Market Cap | $3.33B | $9.01B |
Sector | Health | Financials |
52-Week High | $22.37 | $96.08 |
52-Week Low | $10.24 | $66.70 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Western Alliance Bancorporation (WAL) trades at $82.50, up 1.18% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with a P/E of 9.6 and net income margin of 25.63%. Recent news highlights business expansion and industry recognition, including a #1 ranking in Arizona by Forbes.
The outlook is positive, driven by earnings momentum and a consensus price target of $90.67, offering ~10% upside. Risks include negative operating cash flow and high interest expenses, but strong institutional buy ratings and recent corporate developments support a favorable investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
